Scavone J M, Ochs H R, Greenblatt D J, Matlis R
Department of Psychiatry, Tufts University School of Medicine, Boston, MA.
Eur J Clin Pharmacol. 1988;35(1):105-8. doi: 10.1007/BF00555518.
The kinetics of a single 1200 mg oral dose of oxaprozin, a nonsteroidal antiinflammatory agent of the propionic acid class, was studied in 22 healthy female volunteers aged 21 to 64 years. Eleven subjects had been taking a conjugated estrogen preparation for at least 3 months; the other 11 subjects served as control women who were not taking conjugated estrogens. Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.1 l; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 micrograms/ml, respectively. None of the differences were significant. However, the time of peak concentration (8.9 vs 4.0 h) was significantly longer in the control group than in the conjugated estrogen group, respectively (p less than 0.05). Oxaprozin clearance, accomplished by a combination of oxidation and conjugation, is unimpaired by coadministration of conjugated estrogens.
对22名年龄在21至64岁的健康女性志愿者进行了研究，观察单次口服1200毫克奥沙普秦（一种丙酸类非甾体抗炎药）后的药代动力学情况。11名受试者服用共轭雌激素制剂至少3个月；另外11名受试者作为未服用共轭雌激素的对照女性。对照组和共轭雌激素组的平均药代动力学变量分别为：分布容积，15.1对14.1升；消除半衰期，59.8对54.2小时；清除率，3.2对3.1毫升/分钟；血浆峰浓度，84.8对90.7微克/毫升。这些差异均无统计学意义。然而，对照组的达峰时间（8.9对4.0小时）明显长于共轭雌激素组（p<0.05）。奥沙普秦通过氧化和结合作用实现清除，联合使用共轭雌激素对其清除无影响。
